Dr. Clifford Hudis, the ASCO CEO, shares ASCO’s approach to the continued ABIM-MOC saga. With many oncologists expressing their angst about the MOC process, ASCO, under his leadership, approached the situation methodically, sending a survey to its members to quantify the problem and explore next steps. This is the FIRST time the results of this survey are shared publicly. Learn about Dr. Hudis’s inspiring career journey, his leadership style, and how he and ASCO are addressing this MOC Dilemma. This is a must-listen episode; be the first to know what has happened within ASCO and what the next steps might be.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
